Authors: Seifirad S PMID: 32575019 PMCID: PMC7297676 DOI: 10.1016/j.mehy.2020.110005 Abstract Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects. Pirfenidone is [...]

Ivermectin was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro, which has led to off-label use, but clinical efficacy has not been described previously.

Authors: Elharrar X, Trigui Y, Dois AM, Touchon F PMID: 32412581 PMCID: PMC7229532 DOI: 10.1001/jama.2020.8255 Abstract This case series describes the proportion of awake, nonintubated inpatients with COVID-19 and hypoxemic respiratory failure requiring oxygen supplementation whose Pao2 increased ≥20% with prone positioning, and their respiratory status after resuming supine positioning. Keywords: prone positioning, COVID-19, hypoxemic [...]

This Pilot clinical trial conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of IVM 200Mcg /kg on admission day as add on therapy to hydroxychloroquine (HCQ)and Azithromycin (AZT) and were compared with 71 controls received HCQ and AZT matched in age, gender, clinical features, and comorbidities.

Authors: Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G PMID: 32508062 PMCID: PMC7288983 DOI: 10.1002/ctm2.44 Abstract Patients with severe COVID-19 disease have been characterized as having the acute respiratory distress syndrome (ARDS). Critically ill COVID-19 patients have relatively well-preserved lung mechanics despite severe gas exchange abnormalities, a feature not consistent with classical ARDS [...]

Authors: Guan W, Ni Z, Hu Y, Liang W, Ou C, He J PMCID: PMC7266766 doi: 10.1016/j.jemermed.2020.04.004 Abstract The novel coronavirus (SARS-CoV-2, causing COVID-19) was originally isolated in Wuhan, China. This virus spread quickly throughout many countries in Asia and now Europe, Australia, North America, leading the World Health Organization to declare COVID-19 a pandemic. [...]

Authors: Castillo RR, Quizon GR, Juco MJ, Roman AD, de Leon DG, Punzalan FE et al. DOI:https://doi.org/https://doi.org/10.32794/mr11250063. Abstract Treatment for coronavirus disease 2019 (COVID19) pneumonia remains empirical and the search for therapies that can improve outcomes continues. Melatonin has been shown to have anti-inflammatory, antioxidant, and immune-modulating effects that may address key pathophysiologic mechanisms in [...]

Authors: Henriquez MS, de Tejada Romero MJ PMID: 32486496 PMCID: PMC7352679 doi: 10.3390/nu12061617 Abstract Vitamin D deficiency is a global health problem due to its high prevalence and its negative consequences on musculoskeletal and extra-skeletal health. In our comparative review of the two exogenous vitamin D supplementation options most used in our care setting, we [...]

Authors: Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R PMID: 32473642 PMCID: PMC7261036 DOI: 10.1186/s12941-020-00368-w Abstract The recent report by Caly et al., describing the antiviral potential of ivermectin against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro arrive to the agenda of potential candidates for COVID-19 treatment. This discovery gave [...]

Authors: Jacobs JJ PMID: 32512289 PMCID: PMC7832094 DOI: 10.1016/j.mehy.2020.109884 Abstract SARS-CoV-2 is a novel beta-coronavirus causing over 200.000 lethal cases within six months of first infecting humans. SARS-CoV-2 causes COVID-19, a form of severe acute respiratory syndrome (SARS). COVID-19 is characterized by two phases: the first resembles the flu with pneumonia, but after about seven [...]